Pharmaceuticals

ENWEI PHARMACEUTICAL

ENWEI PHARMACEUTICAL released FY2026 Q1 earnings on April 26 After-Market BJT, actual revenue CNY 175.33 M, actual EPS CNY 0.1212

ENWEI PHARMACEUTICAL released FY2025 Q4 earnings on April 26 After-Market (BJT), actual revenue CNY 263.92 M, actual EPS CNY 0.1366

ENWEI PHARMACEUTICAL released FY2025 earnings on April 26 After-Market BJT, actual revenue CNY 900.77 M, actual EPS CNY 0.5041

ENWEI PHARMACEUTICAL FY2026 Q1 Earnings Release on April 27 After-Market (BJT)

ENWEI PHARMACEUTICAL FY2025 Earnings Release on April 27, 2026 After-Market BJT

ENWEI PHARMACEUTICAL released FY2025 9 Months earnings on October 29 After-Market (BJT), actual revenue CNY 636.85 M, actual EPS CNY 0.3662

ENWEI PHARMACEUTICAL released FY2025 Q3 earnings on October 29 After-Market BJT, actual revenue CNY 187.63 M, actual EPS CNY -0.0176

ENWEI PHARMACEUTICAL FY2025 Q3 Earnings Release on October 30, 2025 After-Market (BJT)

ENWEI PHARMACEUTICAL released FY2025 Q2 earnings on August 25 After-Market BJT, actual revenue CNY 252.72 M, actual EPS CNY 0.2207

ENWEI PHARMACEUTICAL released FY2025 Semi-Annual earnings on August 25 After-Market (BJT), actual revenue CNY 449.22 M, actual EPS CNY 0.3838

ENWEI PHARMACEUTICAL FY2025 Semi-Annual Earnings Release on August 26, 2025 (BJT)

Subsidiary of ENWEI Pharmaceutical Obtains Renewed Drug Production License

Chengdu Jiawei's Shareholding Ratio of Enwei Pharmaceutical Reaches 1%

Enwei Pharmaceutical Reports Significant Q1 2025 Earnings Growth

ENWEI PHARMACEUTICAL released FY2025 Q1 earnings on April 20 During-Market (BJT), actual revenue CNY 196.5 M, actual EPS CNY 0.1631

ENWEI PHARMACEUTICAL released FY2024 Q4 earnings on April 20 During-Market (BJT), actual revenue CNY 251.79 M, actual EPS CNY 0.1552

ENWEI PHARMACEUTICAL released FY2024 annual earnings on April 20 During-Market (BJT), actual revenue CNY 812.13 M, actual EPS CNY 0.3714

ENWEI PHARMACEUTICAL to release FY2025 Q1 earnings on April 21 During-Market BJT

ENWEI PHARMACEUTICAL to Release FY2024 Annual Earnings on April 21 During-Market BJT

Enwei Pharmaceutical and its subsidiaries obtain drug production licenses

301331

ENWEI PHARMACEUTICAL announced that Vice President Chen Lei has reduced his holdings in the company by 16,200 shares through centralized bidding on August 26, 2025, at an average price of 38.65 yuan/share, representing a reduction ratio of 0.0157%; after the reduction, he holds 48,918 shares, accounting for 0.0475% of the total share capital

Zhitong

ENWEI PHARMACEUTICAL: Vice President completes a reduction of 0.0157%

002873

300158

002317

002412

600594

The A-share traditional Chinese medicine sector rapidly surged, with Xintian Pharma hitting the limit up, and YIBAI PHARMACEUTICAL, Zhendong Pharmacy, ZHONGSHENGYAOYE, Hansen Pharmaceutical, and ENWEI PHARMACEUTICAL following suit

Xintian Pharma

Zhendong Pharmacy

ZHONGSHENGYAOYE

Hansen Pharmaceutical

YIBAI PHARMACEUTICAL

ENWEI PHARMACEUTICAL announced that the company's vice president Chen Lei holds 65,118 shares, accounting for 0.0633% of the company's total share capital and 0.0644% of the total share capital after excluding repurchased shares. He plans to reduce his holdings by no more than 16,279 shares through centralized bidding within three months after the 15 trading days following the announcement of this reduction plan, accounting for 0.0158% of the company's total share capital and 0.0161% of the total share capital after excluding repurchased shares. The shares to be reduced come from equity incentive grants, and the reduction price will be determined based on the market price at the time of implementation

ENWEI PHARMACEUTICAL: Vice President plans to reduce holdings by 0.0158% of shares

ENWEI PHARMACEUTICAL announced that its controlling shareholder's concerted actor Chengdu Jiewei will increase its holdings of the company's shares by 199,100 shares through centralized bidding by May 7, 2025, raising its shareholding ratio from 67.83% to 68.02%

ENWEI PHARMACEUTICAL: Chengdu Jiewei has cumulatively increased its holdings in the company by 199,100 shares

ENWEI PHARMACEUTICAL released its 2024 annual report, with operating revenue of 812 million yuan, a year-on-year increase of 3.43%; net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%; net profit excluding non-recurring gains and losses of 34.7296 million yuan, a year-on-year decrease of 52.80%; basic earnings per share of 0.3728 yuan/share. The company plans to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares

ENWEI PHARMACEUTICAL released its 2024 annual performance, with a net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%

According to the Zhitong Finance APP, ENWEI PHARMACEUTICAL disclosed its first-quarter report for 2025, showing that the company achieved revenue of 196 million yuan during the reporting period, a year-on-year increase of 7.10%; net profit attributable to the parent company was 16.31 million yuan, a year-on-year increase of 93.56%; and net profit excluding non-recurring gains and losses was 14.62 million yuan, a year-on-year increase of 118.93%. The basic earnings per share were 0.1635 yuan

ENWEI PHARMACEUTICAL released its first-quarter performance, with a net profit attributable to the parent company of 16.31 million yuan, a year-on-year increase of 93.56%

ENWEI PHARMACEUTICAL announced that its wholly-owned subsidiaries Henan Xinxin Pharmaceutical, Sichuan ENWEI Pharmaceutical, and ENWEI Pharmaceutical have recently received the "Drug Production License" reissued by the drug regulatory authorities. The production address of Henan Xinxin Pharmaceutical is in Zhengzhou and Chengdu, with a production scope that includes tablets and granules; Sichuan ENWEI Pharmaceutical's production address is in Chengdu, with a production scope that also includes tablets and granules; ENWEI Pharmaceutical's production address is in Ji'an, Jiangxi Province, with a production scope that includes mixtures and oral solutions. In addition, Henan Xinxin Pharmaceutical has also entrusted ENWEI Pharmaceutical to produce various drugs

ENWEI PHARMACEUTICAL: Wholly-owned subsidiary obtained the renewed "Drug Manufacturing License"

600000

ENWEI PHARMACEUTICAL's controlling shareholder, Chengdu Jiewei, plans to increase its holdings of the company's A-shares within the next 6 months, with an increase amounting to between 36 million yuan and 72 million yuan. This move aims to enhance investor confidence. Chengdu Jiewei has obtained a special loan commitment from the Chengdu branch of SPD Bank, with the loan amount not exceeding 50 million yuan, specifically for the purpose of increasing shareholdings

SPD Bank

ENWEI PHARMACEUTICAL's controlling shareholder's concerted action party plans to spend between 36 million and 72 million yuan to increase its shareholding

ENWEI PHARMACEUTICAL released its 2024 performance forecast, expecting a net profit of RMB 38 million to RMB 48 million, a year-on-year decrease of 55.97%-44.39%. The net profit after deducting non-recurring gains and losses is expected to be RMB 35 million to RMB 45 million, a year-on-year decrease of 52.44%-38.85%

ENWEI PHARMACEUTICAL issued a profit warning, expecting a net profit of 38 million to 48 million yuan for the year 2024, a year-on-year decrease of 55.97% to 44.39%

ENWEI PHARMACEUTICAL(301331.SZ)